335 related articles for article (PubMed ID: 22028491)
1. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
[TBL] [Abstract][Full Text] [Related]
2. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
[TBL] [Abstract][Full Text] [Related]
3. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
4. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
6. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
Servais EL; Colovos C; Rodriguez L; Bograd AJ; Nitadori J; Sima C; Rusch VW; Sadelain M; Adusumilli PS
Clin Cancer Res; 2012 May; 18(9):2478-89. PubMed ID: 22371455
[TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
9. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
Reardon ES; Shukla V; Xi S; Gara SK; Liu Y; Straughan D; Zhang M; Hong JA; Payabyab EC; Kumari A; Richards WG; De Rienzo A; Hassan R; Miettinen M; Xi L; Raffeld M; Uechi LT; Li X; Wang R; Chen H; Hoang CD; Bueno R; Schrump DS
J Thorac Oncol; 2021 Jan; 16(1):89-103. PubMed ID: 32927122
[TBL] [Abstract][Full Text] [Related]
10. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.
Smits M; Nilsson J; Mir SE; van der Stoop PM; Hulleman E; Niers JM; de Witt Hamer PC; Marquez VE; Cloos J; Krichevsky AM; Noske DP; Tannous BA; Würdinger T
Oncotarget; 2010 Dec; 1(8):710-20. PubMed ID: 21321380
[TBL] [Abstract][Full Text] [Related]
11. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.
Li H; Bitler BG; Vathipadiekal V; Maradeo ME; Slifker M; Creasy CL; Tummino PJ; Cairns P; Birrer MJ; Zhang R
Cancer Prev Res (Phila); 2012 Mar; 5(3):484-91. PubMed ID: 22144423
[TBL] [Abstract][Full Text] [Related]
12. Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma.
Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Yokoi K; Osada H; Sekido Y
J Thorac Oncol; 2012 May; 7(5):890-9. PubMed ID: 22722789
[TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.
Choudhury SR; Balasubramanian S; Chew YC; Han B; Marquez VE; Eckert RL
Carcinogenesis; 2011 Oct; 32(10):1525-32. PubMed ID: 21798853
[TBL] [Abstract][Full Text] [Related]
14. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase.
Derfoul A; Juan AH; Difilippantonio MJ; Palanisamy N; Ried T; Sartorelli V
Carcinogenesis; 2011 Nov; 32(11):1607-14. PubMed ID: 21828058
[TBL] [Abstract][Full Text] [Related]
15. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
17. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
20. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]